John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

Editorial

Stem cell transplantation and CMS: Extreme (hospital at) home makeover

HemOnc Today, August 10, 2017
John Sweetenham, MD
“It’s no wonder that truth is stranger than fiction. Fiction has to make sense.” – Mark Twain
Editorial

‘Port-alisib’ and ‘reach-out-to-me-mab’: A novel combination extends OS in a range of cancer types

HemOnc Today, July 10, 2017
John Sweetenham, MD, FRCP, FACP
Before you Google this combination to figure out how you missed the presentation at the ASCO Annual Meeting, please read on. I do not want you to…
Editorial

‘Special focus’ required to eliminate disparities among millennials with cancer

HemOnc Today, June 10, 2017
John Sweetenham, MD
Last week was a first for me — I participated in a Facebook live event. I had no idea what to expect, but a group of very smart — and…
Editorial

Healthy — and not so healthy — competition

HemOnc Today, May 10, 2017
John Sweetenham, MD
ASCO published its annual report on the state of cancer care in America earlier this spring. As in previous years, the report highlights significant…
Editorial

The cost of living: Financial constraints put benefits of revolutionary treatments at risk

HemOnc Today, April 10, 2017
John Sweetenham, MD
In early March, long-term follow up results of the IRIS trial appeared in The New England Journal of Medicine. This study, opened in 2000, compared…
Editorial

Reflections on the value of new cancer drugs: The role of the man in the mirror

HemOnc Today, March 10, 2017
John Sweetenham, MD
The cost of cancer drugs has been the subject of intense interest and scrutiny. This is no surprise as the focus on value in cancer care increases…
Editorial

Despite challenges in US cancer care, things could be a lot worse

HemOnc Today, February 10, 2017
John Sweetenham, MD
“When my bankroll is getting small I think of when I had none at all
Editorial

Valuing communication and communicating value: Staying in touch with our patients’ priorities

HemOnc Today, January 10, 2017
John Sweetenham, MD
Although the presidential election result has raised questions about the direction of health care reform, most experts believe that value will remain…
Editorial

Doing the same thing over and over again but expecting different results: It’s time to move on

HemOnc Today, November 25, 2016
John Sweetenham, MD
A publication in Journal of Clinical Oncology reports the results of a randomized trial that compared rituximab, cyclophosphamide, doxorubicin…
Editorial

Cancer screening: The stars are aligned

HemOnc Today, November 10, 2016
John Sweetenham, MD
In recent weeks, important new studies have added more data to the ongoing debate about the effectiveness of screening programs for breast cancer and…